Illumina Inc. ($ILMN) Stock Forecast: Up 5.2% Today

What is Illumina Inc.?

Illumina Inc. (ILMN) operates in the genomics sector, specializing in genetic sequencing and array-based technologies. The stock exhibited a strong bullish movement today.

Why is Illumina Inc. going up?

ILMN stock is up 5.2% on May 1, 2026 13:51

• Better-than-expected Q1 2026 earnings were reported by Illumina, surpassing analyst estimates for revenue and non-GAAP EPS. This was driven by high demand for sequencing consumables and instruments in clinical applications.
• The company increased its full-year 2026 guidance, showing confidence in ongoing growth, notably in clinical markets, despite supply chain challenges and caution in research sectors.
• Although there was a slight decline after the earnings announcement, Illumina's effective operations and promising future suggest a positive quarter for investors. After-hours trading saw a 5.29% increase, outperforming competitors on a strong trading day.
• Illumina's introduction of a new $1.5 billion share repurchase program underscores its faith in the business strategy and financial outlook, bolstering positive market sentiment and the rise in the stock price.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Earnings call transcript: Illumina beats Q1 2026 estimates, stock rises

Illumina Inc. reported stronger-than-expected Q1 2026 earnings, with both revenue ($1.09 billion) and non-GAAP EPS ($1.15) surpassing analyst estimates. This performance was driven by robust demand for sequencing consumables and instruments, particularly in clinical applications, leading to a 5.29% rise in after-hours trading. The company raised its full-year 2026 guidance, reflecting confidence in continued growth, especially in clinical markets, despite ongoing supply chain constraints and cautiousness in research sectors.

https://www.investing.com/news/transcripts/earnings-call-transcript-illumina-beats-q1-2026-estimates-stock-rises-93CH-4651581

|Illumina (NASDAQ:ILMN) Posts Better-Than-Expected Sales In Q1 CY2026

|Illumina (NASDAQ:ILMN) reported strong Q1 CY2026 results, surpassing Wall Street's revenue and EPS expectations with sales up 4.8% year-on-year to $1.09 billion and non-GAAP profit exceeding estimates by 9%. The company also raised its full-year revenue and Adjusted EPS guidance. Despite a slight post-earnings stock dip, the company's efficient operations and promising outlook suggest a decent quarter for investors.

https://www.tradingview.com/news/stockstory:c819c4465094b:0-illumina-nasdaq-ilmn-posts-better-than-expected-sales-in-q1-cy2026/

Earnings Flash (ILMN) Illumina, Inc. Reports Q1 Revenue $1.09B, vs. FactSet Est of $1.07B

Illumina, Inc. (ILMN) reported Q1 revenue of $1.09 billion, exceeding FactSet's estimate of $1.07 billion. This announcement indicates stronger-than-expected financial performance for the quarter. The company also provided an updated outlook for fiscal year 2026.

https://www.marketscreener.com/news/earnings-flash-ilmn-illumina-inc-reports-q1-revenue-1-09b-vs-factset-est-of-1-07b-ce7f58d8df89f422

[8-K] ILLUMINA, INC. Reports Material Event

Illumina, Inc. (NASDAQ: ILMN) reported strong financial results for the first quarter of fiscal year 2026, with revenue up 4.8% to $1.09 billion and non-GAAP diluted EPS increasing to $1.15. The company also raised its full-year 2026 guidance for revenue to $4.52–$4.62 billion and non-GAAP EPS to $5.15–$5.30. Additionally, Illumina's board authorized a new $1.5 billion share repurchase program, demonstrating confidence in its business strategy and financial outlook.

https://www.stocktitan.net/sec-filings/ILMN/8-k-illumina-inc-reports-material-event-babfbb911902.html

Illumina Inc. stock outperforms competitors on strong trading day

Illumina Inc. (ILMN) saw its stock rally 5.29% to $126.74, outperforming the broader market indices like the S&P 500 and Dow Jones Industrial Average on a strong trading day. This increase ended a two-day losing streak for the company's shares.

https://www.marketwatch.com/data-news/illumina-inc-stock-outperforms-competitors-on-strong-trading-day-dd6937ad-e3ad95b239d9?mod=mw_quote_news

Trending Today

Brent Crude Oil ($BRENT) Commodity Forecast: Up 5.9% Today

Tilray Inc. ($TLRY) Stock Forecast: Down 5.1% Today

Sonos Inc. ($SONO) Stock Forecast: Down 0.8% Today

CleanSpark Inc ($CLSK) Stock Forecast: Up 5.4% Today

Digital Ocean Holdings ($DOCN) Stock Forecast: Up 5.1% Today

Circle Internet Group ($CRCL) Stock Forecast: Up 7.5% Today

Crude Oil ($CRUDE) Commodity Forecast: Up 5.0% Today

Kohl's Corporation ($KSS) Stock Forecast: Down 5.7% Today

Tandem Diabetes Care, Inc. ($TNDM) Stock Forecast: Down 5.0% Today

Blink Charging Co. ($BLNK) Stock Forecast: Down 5.3% Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.1%

• The bullish movement in Illumina's stock could be attributed to the company's partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to launch the Billion Cell Atlas initiative. This ambitious project aims to map genetic perturbations in five billion human cells, providing valuable insights for drug discovery and precision medicine.
• The collaboration with major pharmaceutical companies highlights Illumina's commitment to advancing genomic research and its potential to revolutionize the field of AI-driven drug discovery.
• The emphasis on creating a comprehensive genetic dataset to accelerate drug discovery and improve target validation likely resonated positively with investors, driving the bullish market movement in Illumina's stock today.

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.01.2026 - ILMN Stock was down 12.3%

• Despite strong Q4 2025 earnings that surpassed expectations, Illumina's stock saw a notable decline following a cautious 2026 revenue outlook.
• Investor response suggests disappointment with the company's conservative forecast for the upcoming period, despite its previous strong performance.
• Illumina's strategic focus on core sequencing, multiomics scaling, and data/software expansion is contributing to its momentum. However, concerns around the subdued 2026 revenue guidance seemed to overshadow these accomplishments for investors.
• While the company remains optimistic about the growing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument in clinical settings, these positive prospects were unable to offset worries about future growth potential, resulting in a bearish trend for the stock.

06.01.2026 - ILMN Stock was down 9.6%

• Despite surpassing Q4 earnings forecasts, Illumina's stock trended bearishly due to its conservative 2026 revenue guidance, disappointing investors who were anticipating a more aggressive outlook.
• The market's response suggests that investors are evaluating Illumina's robust operational performance in Q4 against its unchanging annual revenue for 2025, which paralleled the previous year.
• Although Illumina offered a positive forecast for 2026, anticipating revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, the stock's decline indicates that investors possibly anticipated more ambitious future projections.
• The contrast between the company's solid financial performance and the market's reaction underscores the significance of managing investor expectations and articulating a compelling growth narrative for forthcoming results.

27.02.2026 - ILMN Stock was down 5.9%

• Illumina's stock experienced a bearish movement due to regulatory scrutiny over its past Grail acquisition and a slowdown in the biotech sector, leading to softening demand in genomic sequencing and increased competition.
• The short-term corrective bearish wave, negative pressure from technical indicators like the 50-day SMA and overbought Stochastic indicators, contributed to the decline in Illumina's stock price.
• Despite positive news such as Nordea Investment Management AB significantly increasing its stake in Illumina and the company reporting strong Q4 earnings, the mixed analyst sentiment and challenges in the industry have put pressure on the stock.
• The launch of Illumina's TruPath™ Genome tool aims to provide deeper insights into complex genomic regions, showcasing the company's commitment to advancing genomic research amidst market challenges.

24.01.2026 - ILMN Stock was up 5.6%

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

30.03.2026 - ILMN Stock was up 5.4%

• Illumina Inc. experienced a bullish trend today, with its stock price advancing by 1.95% to $127.88, breaking a recent losing streak.
• The anticipation of the Q1 2026 earnings release created positive sentiment among investors, who were eager to receive updates on core sequencing revenue and guidance.
• The revision in Illumina's stock evaluation, showcasing strong financial metrics like a P/E ratio of 36 and a robust ROCE of 28.32%, likely contributed to the bullish movement.
• The projected growth in the Human Microbiome Sequencing Technology market, where Illumina is a key player, could have also influenced investor optimism, especially with the company's focus on innovation and strategic partnerships in the sector.

01.04.2026 - ILMN Stock was up 5.2%

• Better-than-expected Q1 2026 earnings were reported by Illumina, surpassing analyst estimates for revenue and non-GAAP EPS. This was driven by high demand for sequencing consumables and instruments in clinical applications.
• The company increased its full-year 2026 guidance, showing confidence in ongoing growth, notably in clinical markets, despite supply chain challenges and caution in research sectors.
• Although there was a slight decline after the earnings announcement, Illumina's effective operations and promising future suggest a positive quarter for investors. After-hours trading saw a 5.29% increase, outperforming competitors on a strong trading day.
• Illumina's introduction of a new $1.5 billion share repurchase program underscores its faith in the business strategy and financial outlook, bolstering positive market sentiment and the rise in the stock price.

23.03.2026 - ILMN Stock was down 5.3%

• Illumina Inc. (ILMN) saw a 1.34% increase in its stock value, falling behind its industry peers, possibly indicating weaknesses in its competitive position.
• The stock's fifth consecutive day of gains may have prompted investors to take profits, leading to downward pressure on its price.
• Despite positive performances in the market with the S&P 500 and Dow Jones Industrial Average both rising, the decline in Illumina's stock could be attributed to internal factors rather than broader market trends.

29.03.2026 - ILMN Stock was down 5.2%

• The downward trend in Illumina's stock today could be due to profit-taking following a recent increase in value.
• Insider selling by Universal Beteiligungs und Servicegesellschaft mbH may have influenced market sentiment, leading to a decrease in the stock price.
• Despite strong financial metrics and outperforming competitors on Friday, consecutive days of losses and broader market trends may have contributed to the downward movement.
• Competition in the Human Microbiome Sequencing Technology market, where Illumina is a prominent player, could also be impacting investor sentiment and trading patterns.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.